Texas-based biotechnology firm Cassava Sciences has halted an advanced clinical trial for the experimental Alzheimer's drug simufilam after it failed to significantly reduce cognitive decline in people with mild to moderate Alzheimer's disease. According to the New York Times, the canceled trial comes after several foundational studies to support the drug were found to contain fraudulent data and subsequently retracted from scientific journals. Cassava Sciences was also forced to settle with the Securities and Exchange Commission in September over allegations of misleading statements about earlier trial results.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.